Table: Solasia Pharma -9-MTH group results (IFRS)

Solasia Pharma KK

13/11/2023 06:30

Nov 13 (Reuters)- 
              Solasia Pharma K. K. 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   9 months ended      9 months ended       Year to 
                  Sep 30, 2023        Sep 30, 2022     Dec 31, 2023 
                     LATEST             YEAR-AGO          COMPANY   
                     RESULTS             RESULT          FORECAST   
  Sales              602 mln             485 mln                    
                   (+24.3 pct)         (+71.3 pct)                  
  Operating       loss 787 mln          loss 1.95                   
  Pretax          loss 784 mln          loss 1.97                   
  Net             loss 768 mln          loss 2.05                   
  EPS Basic       loss 4.57 yen      loss 13.98 yen                 
  EPS Diluted     loss 4.57 yen      loss 13.98 yen                 
  Ann Div                                  NIL              NIL     
  -Q2 Div              NIL                 NIL                      
  -Q4 Div                                  NIL              NIL     
 
  NOTE - Solasia Pharma K. K.. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4597.T